狼疮肾炎靶向B细胞治疗研究新进展

Research advances in targeted therapy of lupus nephritis

狼疮肾炎(lupus nephritis,LN)是系统性红斑狼疮严重的并发症之一,也是中国常见的继发性肾小球肾炎。目前临床上无法治愈LN,只能通过激素联合免疫抑制剂来缓解症状,延缓肾功能衰退。然而现有的治疗方案对LN的完全肾脏缓解率偏低,而且疾病容易复发。近年来,随着LN发病机制的深入研究,以B细胞为靶点的各种生物制剂、治疗手段以及抗细胞因子活化的生物制剂不断被研发。因此,本文就目前靶向生物制剂和治疗手段在LN的临床研究现状做一综述,旨在为临床医生提供治疗新思路。

As the most common secondary glomerulonephritis in China,lupus nephritis(LN)is one of the most severe consequences of systemic lupus erythematosus(SLE).Currently the sole option of treating LN clinically is with hormones plus immunosuppressants for managing symptoms and arresting the loss of renal function.However,recurrent remains high due to a low complete remission rate of LN.With in-depth pathophysiological understandings of LN,numerous biological agents and therapeutic tech-niques targeting B cells as well as biological agents against cytokine activation have been developed in re-cent years.This review summarized the latest advances of targeted biological agents and therapeutic ap-proaches to provide references for clinical practices.